Company Name
DILIGENT LIFE CARE
Year of Establishment
2017
Annual Turnover(USD)
500,000 to 99,999,999
Company Introduction
Founded in 2017, Diligent Life Care is a leading pharmaceutical company specializing in the manufacturing and supply of Active Pharmaceutical Ingredients (APIs) for both human and veterinary applications. Our manufacturing facility and registered office are located in Ahmedabad, Gujarat, with a Marketing Office in Mumbai.
With deep industry expertise and insight, we cater to the evolving needs of the global pharmaceutical sector, consistently delivering high-quality APIs that meet the highest standards of quality and compliance.
Commitment to Quality & Certification
Our manufacturing unit is STATE GMP accredited, and we are actively working toward WHO GMP certification to solidify our position as a globally recognized manufacturing company. The Diligent Technical Centre, built to GLP standards, serves as the backbone of our success, encompassing R&D, Process Development (PD), and a Kilo Lab.
Our goal is to become the preferred supply partner in expanding global markets by offering innovative, high-quality, cost-effective, and environmentally responsible APIs. With a strong focus on Product & Process Research, the company is a leading manufacturer of Anti-inflammatory drugs (NSAIDs), Antiparasitic, Antipsychotic, Anthelmintic, Vet. Antibacterial, Antidepressant, Antidiabetic, Antispasmodics API’s We proudly supply these critical ingredients to leading pharmaceutical companies in India and across numerous international markets.
At Diligent Life Care, we are not just suppliers — we are your strategic partners in progress.
Main Competitive Advantages
Delivery Term,Buyers' Specifications Accepted,Small Orders Accepted,Reputation,Quality Service,
Website
www.diligentlifecare.com
Milestone
Diligent Life Care.
2017
Established in Ahmedabad, Gujarat (India), with a marketing office in Mumbai.
Commenced manufacturing of Tolfenamic Acid (Anti-Inflammatory) and Marbofloxacin (Vet. Antibacterial) for Human and Veterinary markets.
2019
Began manufacturing of Amitraz (Acaricide / Antiparasitic)
2020
Expanded global operations into over 10 countries, including Bangladesh, Vietnam, South Korea, Uruguay, Egypt, South Africa, Japan, and Poland.
2021
Manufacturing facility approved under Indian State GMP guidelines.
Received Certificate of Source Validation from DGDA, Republic of Bangladesh.
Started manufacturing of Amisulpride (Antipsychotic) and Pregabalin (Anticonvulsant).
2022
Expanded API portfolio with Closantel Base (Anthelmintic).
2023
Secured product approvals in Uruguay, Poland, and Japan.
Commenced commercial supply of Tolfenamic Acid, Marbofloxacin, and Bithionol Sulfoxide under Free Sales Certificate (FSC).
Began manufacturing of Moxidectin.
2024
Achieved financial stability and sustainable growth.
Increased monthly API production capacity and expanded manufacturing infrastructure.
Commenced manufacturing of Closantel Sodium (Anthelmintic)
2025 (In Progress)
Development initiated for:
Melitracen Hydrochloride (Antidepressant)
Flupentixol Dihydrochloride (Antipsychotics)
Linagliptin (Antidiabetic)
Tiemonium Methylsulfate (Antispasmodics)